Keyphrases
B-cell Lymphoproliferative Disorder
16%
BL22
16%
Bone Marrow
16%
Cladribine
100%
Complete Remission
33%
Effective Therapy
16%
Flow Cytometry
16%
Hairy Cell Leukemia
100%
Immunoconjugate
16%
Immunohistochemistry
100%
Immunophenotyping
100%
Leukemia Cells
16%
Marrow
16%
Minimal Residual Disease
100%
Monoclonal Antibody
16%
Natural History
16%
Overall Survival
16%
Patient-specific
16%
Pentostatin
16%
Peripheral Blood Counts
16%
Polymerase Chain Reaction
33%
Purine Analogues
50%
Rituximab
16%
Treatment Choice
16%
Medicine and Dentistry
B Cell
16%
Cladribine
100%
Flow Cytometry
16%
Hairy Cell Leukemia
100%
Immunohistochemistry
100%
Immunophenotyping
100%
Leukemia Cell
16%
Lymphoproliferative Disease
16%
Minimal Residual Disease
100%
Monoclonal Antibody
16%
Morphology
16%
Overall Survival
16%
Pentostatin
16%
Polymerase Chain Reaction
33%
Purine
50%
Rituximab
16%
Neuroscience
B Cell
33%
Cladribine
100%
Flow Cytometry
33%
Immunoconjugate
33%
Immunohistochemistry
100%
Immunophenotyping
100%
Monoclonal Antibody
33%
Pentostatin
33%
Polymerase Chain Reaction
66%
Purine
100%
Rituximab
33%
Pharmacology, Toxicology and Pharmaceutical Science
Cladribine
100%
Flow Cytometry
16%
Hairy Cell Leukemia
100%
Leukemia
16%
Lymphoproliferative Disease
16%
Minimal Residual Disease
100%
Monoclonal Antibody
16%
Overall Survival
16%
Pentostatin
16%
Purine
50%
Purine Derivative
50%
Remission
33%
Rituximab
16%
Immunology and Microbiology
B Cell
33%
Blood Cell Count
33%
Immunoconjugate
33%
Leukemia Cell
100%
Lymphoproliferative Disorders
33%
Monoclonal Antibody
33%
Morphology
33%
Overall Survival
33%
Polymerase Chain Reaction
66%
Rituximab
33%
Veterinary Science and Veterinary Medicine